Sands Capital

Founded in 1992, Sands Capital is an independent, employee-owned investment management firm based in Arlington, Virginia. It specializes in fundamental, bottom-up research to identify high-quality growth businesses globally, from early-stage private companies to leading public entities across various sectors.

Ian Barnes

Managing Director

Matthew Buckley

Senior Research Associate

Brian Christiansen

Executive Managing Director, Senior Portfolio Manager and Research Analyst

Christopher Eng

Principal

Scott Frederick

Managing Director

Kumar Gautam

Partner

Michael Ginder

Partner

Michael Graninger

Managing Partner

Michael Graninger

Partner

Nicholas Graziano

Principal, Portfolio Services

David Levanson

Senior Portfolio Manager, Research Analyst and Executive Managing Director

Barron Martin Jr.

Managing Partner

Barron Martin

Research Analyst

Annie McCormick

Director, Client Service

Mark McGovern

Venture Partner

Dana McNamara

Executive Managing Director and Chief Administrative Officer

Jake Merrill

Principal

Gene Riechers

Venture Partner

Frank M. Sands, Jr.

CEO, CIO

Marina Serenbetz

Partner

Shreya Singh

Associate

Erin Soule

Managing Director and Head of Private Markets Finance and Operations

Michael Sramek

Managing Director, Research Analyst and Senior Portfolio Manager

Christy Steele

Principal

Past deals in Infants

Vitara Biomedical

Series B in 2024
Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.

Vitara Biomedical

Series B in 2022
Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.